Literature DB >> 19563827

Pharmacogenomics of antidepressant drugs.

Sonja Horstmann1, Elisabeth B Binder.   

Abstract

While antidepressant pharmacotherapy is an effective treatment of depression, it is still hampered by the slow onset of appreciable clinical improvement and a series of side effects. Moreover, a substantial group of patients does not achieve remission or fails to respond at all. One possible source accounting for these variations in treatment outcome are genetic differences. In recent years a number of pharmacogenetic studies on antidepressant drugs have been published. This manuscript summarizes findings related to the pharmacogenetics of genes involved in the pharmacokinetics as well as pharmacodynamics of antidepressants to date. Illustrated by examples from current candidate gene- and whole genome association studies, this manuscript critically discusses aspects of pharmacogenetic studies in antidepressant response related to study design and clinical relevance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19563827     DOI: 10.1016/j.pharmthera.2009.06.007

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  23 in total

Review 1.  Assessing gene-gene interactions in pharmacogenomics.

Authors:  Hsien-Yuan Lane; Guochuan E Tsai; Eugene Lin
Journal:  Mol Diagn Ther       Date:  2012-02-01       Impact factor: 4.074

2.  Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients.

Authors:  Aarthi Manoharan; Deepak Gopal Shewade; Ravi Philip Rajkumar; Surendiran Adithan
Journal:  Eur J Clin Pharmacol       Date:  2016-07-20       Impact factor: 2.953

Review 3.  Identifying genetic loci affecting antidepressant drug response in depression using drug-gene interaction models.

Authors:  Raymond Noordam; Christy L Avery; Loes E Visser; Bruno H Stricker
Journal:  Pharmacogenomics       Date:  2016-06-01       Impact factor: 2.533

4.  Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response.

Authors:  Karen Hodgson; Shaista Jeelani Mufti; Rudolf Uher; Peter McGuffin
Journal:  Genome Med       Date:  2012-06-27       Impact factor: 11.117

Review 5.  Do we need pharmacogenetics to personalize antidepressant therapy?

Authors:  Cristina Lanni; Marco Racchi; Stefano Govoni
Journal:  Cell Mol Life Sci       Date:  2012-12-28       Impact factor: 9.261

6.  The role of GRIK4 gene in treatment-resistant depression.

Authors:  Elena Milanesi; Cristian Bonvicini; Chiara Congiu; Marco Bortolomasi; Giulio Gainelli; Massimo Gennarelli; Alessandra Minelli
Journal:  Genet Res (Camb)       Date:  2015-07-03       Impact factor: 1.588

7.  Changes in sleep quality, but not hormones predict time to postpartum depression recurrence.

Authors:  Michele L Okun; Jim Luther; Aric A Prather; James M Perel; Stephen Wisniewski; Katherine L Wisner
Journal:  J Affect Disord       Date:  2010-08-12       Impact factor: 4.839

Review 8.  Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others.

Authors:  Joseph P Kitzmiller; David K Groen; Mitch A Phelps; Wolfgang Sadee
Journal:  Cleve Clin J Med       Date:  2011-04       Impact factor: 2.321

9.  Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment.

Authors:  Sonja Horstmann; Susanne Lucae; Andreas Menke; Johannes M Hennings; Marcus Ising; Darina Roeske; Bertram Müller-Myhsok; Florian Holsboer; Elisabeth B Binder
Journal:  Neuropsychopharmacology       Date:  2009-11-18       Impact factor: 7.853

10.  Secreted frizzled-related protein 3 (sFRP3) regulates antidepressant responses in mice and humans.

Authors:  M-H Jang; Y Kitabatake; E Kang; H Jun; M V Pletnikov; K M Christian; R Hen; S Lucae; E B Binder; H Song; G-I Ming
Journal:  Mol Psychiatry       Date:  2012-12-04       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.